Phenomenon or Process – Page 2

Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, lung function, forced vital capacity

GLP-1 Weight Loss Drugs Make Super Bowl Advertising Debut Amid Shifting Health Marketing Landscape

7 months ago talkbio0Tagged Epidemic, Glucagon-Like Peptide 1, Health care facility, Hims & Hers, Obesity, pharmaceutical marketing, Super Bowl ads, Weight-Loss Agents

GLP-1, Super Bowl ads, Hims & Hers, weight loss drugs, pharmaceutical marketing, healthcare advertising, obesity epidemic

Trump Withdraws US from World Health Organization, Sparking Concerns Over Global Health Security

7 months ago talkbio0Tagged Communicable Diseases, COVID19 (disease), Generalized, health security, Pandemics, public health medicine (field), Transplant Registry Unified Management Program, WHO, Withdraw (activity), World Health Organization

Trump, World Health Organization, WHO, withdrawal, global health security, infectious diseases, pandemics, COVID-19, public health experts.

PureTech’s Deupirfenidone Demonstrates Superior Efficacy in Slowing Lung Function Decline in Idiopathic Pulmonary Fibrosis (IPF) Patients

8 months ago talkbio0Tagged decline, Force, High, Idiopathic Pulmonary Fibrosis, IPF, Phase 2b Trial, pirfenidone, PureTech Health, Respiratory physiology, Vital capacity, Vital capacity test

Deupirfenidone, Idiopathic Pulmonary Fibrosis (IPF), Lung Function Decline, Forced Vital Capacity (FVC), ELEVATE IPF Phase 2b Trial, PureTech Health

Sarepta Therapeutics Halts Development of Vesleteplirsen, a Next-Generation Exon-Skipping Therapy for Duchenne Muscular Dystrophy

10 months ago talkbio0Tagged Duchenne, Exon-Skipping Therapy, Feedback - system communication, Landscapes, Muscular Dystrophy, Muscular Dystrophy, Duchenne, SRP-5051, United States Food and Drug Administration, Vesleteplirsen

Sarepta Therapeutics, Vesleteplirsen (SRP-5051), Duchenne Muscular Dystrophy (DMD), Exon-Skipping Therapy, FDA Feedback, Therapeutic Landscape

Novartis’ $2.9B MorphoSys Acquisition Hits Roadblock as Safety Concerns Delay Approval Filing

10 months ago talkbio0Tagged delayed approval, MorphoSys, Novartis, Safety, Signal

Novartis, MorphoSys, safety signal, delayed approval, biotech, pharmaceuticals